Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807444 | 0.89 | ADORA1 (0.67) | ADORA1MAPK1IGF1RHTTEGFR | |
| SCHEMBL19829272 | 0.87 | ADORA1 (0.86) | ADORA1MAPK1IGF1RHTTEGFR | |
| SCHEMBL7488213 | 0.87 | ADORA1 (0.66) | ADORA1MAPK1IGF1RHTTKDM4E | |
| SCHEMBL8807266 | 0.85 | ADORA1 (0.88) | ADORA1MAPK1IGF1RHTTKDM4E | |
| SCHEMBL8810012 | 0.85 | ADORA1 (0.73) | ADORA1MAPK1IGF1RHTTEGFR | |
| SCHEMBL7299166 | 0.85 | ADORA1 (0.77) | ADORA1MAPK1IGF1RHTTEGFR | |
| SCHEMBL19829271 | 0.84 | ADORA1 (0.66) | ADORA1MAPK1IGF1RHTTEGFR | |
| SCHEMBL7304113 | 0.84 | ADORA1 (0.68) | ADORA1MAPK1IGF1RPTGDR2 | |
| SCHEMBL2641189 | 0.84 | ADORA1 (1.00) | ADORA1MAPK1IGF1RHTTKDM4E | |
| SCHEMBL8807841 | 0.84 | ADORA1 (0.77) | ADORA1MAPK1IGF1RHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10182643-A | — | — | None | — | — | JP | disclosed |
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| JP-H10182643-A | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTIC AGENT | FUJISAWA PHARMACEUT CO LTD | 1998-07-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | NT5E, ADORA1, ENTPD5 | ADORA1 2/4885MAPK1 3104/4885IGF1R 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.